Zoetis Receives a Conditional License from USDA for Canine Atopic Dermatitis Treatment

Itching is among the most frequent complaints of pet owners, affecting roughly 1 in 6 dogs whose owners seek veterinary help.

There are a number of factors that can trigger an itch reaction, such as infections, otitis and parasites—and approximately 15-20 percent of all itchy dogs will be diagnosed with atopic dermatitis.

Today Zoetis Inc. announced that the U.S. Department of Agriculture (USDA) has granted the company a conditional license for Canine Atopic Dermatitis Immunotherapeutic, a first-of-its-kind antibody therapy to help reduce clinical signs associated with atopic dermatitis in dogs. It represents another major innovation to emerge from the proprietary research and development platform Zoetis has built based on new scientific insights into the pathway of allergic skin conditions.